Antisense technology represents an important breakthrough in the way we treat disease. The explosion in genomic information led to the discovery of many new disease-causing proteins and created new opportunities accessible only to antisense technology.
We have led the industry in the development of RNA-targeted technologies and successfully developed a drug discovery platform based on our antisense technology. We discover and develop drugs that bind to RNA instead of proteins, which have been the focus of the pharmaceutical industry for more than 100 years.
For information on the targets and the mechanisms by which antisense drugs work read more here
We know that sick people depend on us, and we have the technology to change the way diseases are treated.Learn More
Our pipeline continues to grow with novel therapies in development to treat patients who have significant medical needs.Learn More
Isis Pharmaceuticals is currently enrolling a Phase 3 study that is designed to evaluate the safety and efficacy of ISIS-TTRRx in patients with Familial Amyloid Polyneuropathy (FAP), the form of TTR amyloidosis that causes nerve damage.Learn More About the Study